Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well olanzapine works in managing cancer cachexia in patients experiencing esophagogastric, hepatopancreaticobiliary, colorectal, or lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) -associated appetite loss while receiving non-curative cancer therapy. Loss of appetite ("anorexia") in the setting of cancer is a key feature of "cachexia," a syndrome associated with loss of weight and muscle as well as weakness and fatigue. Olanzapine is a drug that targets key neurotransmitters (a type of molecule in the central nervous system that transmits messages to the rest of the body) that may stimulate appetite, restore caloric intake, minimize weight loss, and improve quality of life (QOL).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony zaawansowany lub przerzutowy rak przełyku, żołądka, wątroby, trzustki, jelita grubego lub płuc zdiagnozowany w ciągu ostatnich 12 tygodni
- •Utrata wagi: co najmniej 5% przez ostatnie 6 miesięcy lub 2% przy niedowadze
- •Otrzymywanie pierwszej linii leczenia onkologicznego (chemioterapia, terapia celowana lub immunoterapia)
- •Zdolność do samodzielnego poruszania się z pomocą lub bez niej
- •W przypadku przerzutów do mózgu: bez objawów i wyleczony/wyleczona z powodzeniem
- •Ocena stanu zdrowotnego ECOG 0-2 (pacjent może wykonywać swoją pracę)
- •Gotowość do zaprzestania zażywania leków kolidujących z badaniem i stosowania antykoncepcji
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
OHSU Knight Cancer Institute
Portland, United States
Trial contact
Eric Roeland, M.D., FAAHPM, FASCO
Eric Roeland, M.D., FAAHPM, FASCO
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.